40 In capital markets, Saltzman led private placements of units for Innocan Pharma Corporation, a pharmaceutical technology company headquartered in Israel. The company operates in two primary sectors: pharmaceuticals and consumer wellness. A key figure in Gowling’s Dubai office, Jon Parker works with Israeli life sciences companies on IP issues, enhancing the protection and commercialization of cutting-edge innovations in a rapidly evolving sector. Gowling WLG was formed from the merger of Canada-based Gowlings and UK-based Wragge Lawrence Graham & Co in February 2016, in the first multinational law firm merger co-led by a Canadian firm. Greenberg Traurig With a multidisciplinary office in Tel Aviv, Greenberg Traurig’s Israel Practice— comprising over 100 professionals—serves as a key gateway for Israeli businesses and entrepreneurs seeking global expansion, as well as for international clients looking to establish or grow their presence in Israel. This was backed up in the latest IsraelDesks rankings, which saw the Israel Practice take pole position in High-Tech, ranked an Elite firm in M&A (Volume) and in Capital Markets, storming clear in the volume table. The firm was also an Elite firm in Employment, Real Estate, and taking joint first position in IP. Greenberg Traurig’s Israel Practice operates under the leadership of Managing Shareholder Joey Shabot, who spearheads corporate transactions and commercial disputes involving Israeli entities. In 2024, he represented Wiwyn, a Taiwanese company, in its investment in ZutaCore, an Israeli innovator in direct-to-chip liquid cooling technology for data centers. He also advised Ibex, a U.S.-based ad-tech company, on a VC investment in Israeli startup Arya. Fort Lauderdale-based Bruce March led the counsel to Nano Dimension, an Israel-based leader in Additively Manufactured Electronics (AME), in its acquisitions of Desktop Metal and Markforged Holding Corporation. In capital markets, Gary Emmanuel and Mark Selinger advised Silexion Therapeutics Ltd., an Israeli clinical-stage biotechnology company specializing in oncology treatments, on its SPAC merger with Moringa Acquisition Corp. The team includes David Huberman, well versed in the U.S. IPOs of Israeli companies. They also counseled Gauzy Ltd., an Israeli company specializing in vision and light control technologies, in its USD 75 million Nasdaq IPO in June 2024, and represented OPKO Health Inc., a multinational biopharmaceutical
RkJQdWJsaXNoZXIy MjgzNzA=